BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study - PubMed (original) (raw)
. 2000 Oct 1;60(19):5329-33.
Affiliations
- PMID: 11034065
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study
R L Baldwin et al. Cancer Res. 2000.
Abstract
There is a clear association between germ-line BRCA1 mutations and inherited ovarian cancer; however, the association between BRCA1 mutations and sporadic ovarian cancer remains ambiguous. The frequency of BRCA1 promoter hypermethylation as an epigenetic means of BRCA1 inactivation was determined for a large, population-based cohort of ovarian cancer patients. BRCA1 promoter hypermethylation was determined by methylation-specific restriction digestion of tumor DNA, followed by Southern blot analysis and confirmed by methylation-specific PCR. BRCA1 promoter hypermethylation was observed in 12 of 98 ovarian tumors. BRCA1 methylation status of the primary tumor was conserved in six recurrent tumors after interim chemotherapy. None of the 12 tumors with BRCA1 promoter hypermethylation demonstrated BRCA1 protein expression by immunohistochemistry. BRCA1 methylation was only seen in ovarian cancer patients without a family history suggestive of a breast/ ovarian cancer syndrome. Therefore, the 12 BRCA1 methylated tumors represented 15% (12 of 81) of the sporadic cancers analyzed in this study. Although the clinical significance of BRCA1 promoter hypermethylation is yet to be determined, promoter hypermethylation may be an alternative to mutation in causing the inactivation of the BRCA1 tumor suppressor gene in sporadic ovarian cancer.
Similar articles
- Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Potapova A, Hoffman AM, Godwin AK, Al-Saleem T, Cairns P. Potapova A, et al. Cancer Res. 2008 Feb 15;68(4):998-1002. doi: 10.1158/0008-5472.CAN-07-2418. Cancer Res. 2008. PMID: 18281473 - High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.
Wilcox CB, Baysal BE, Gallion HH, Strange MA, DeLoia JA. Wilcox CB, et al. Cancer Genet Cytogenet. 2005 Jun;159(2):114-22. doi: 10.1016/j.cancergencyto.2004.12.017. Cancer Genet Cytogenet. 2005. PMID: 15899382 - Methylation of the BRCA1 gene in sporadic breast cancer.
Dobrovic A, Simpfendorfer D. Dobrovic A, et al. Cancer Res. 1997 Aug 15;57(16):3347-50. Cancer Res. 1997. PMID: 9269993 - The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer.
McCoy ML, Mueller CR, Roskelley CD. McCoy ML, et al. Reprod Biol Endocrinol. 2003 Oct 7;1:72. doi: 10.1186/1477-7827-1-72. Reprod Biol Endocrinol. 2003. PMID: 14613551 Free PMC article. Review. - A critical re-appraisal of BRCA1 methylation studies in ovarian cancer.
Senturk E, Cohen S, Dottino PR, Martignetti JA. Senturk E, et al. Gynecol Oncol. 2010 Nov;119(2):376-83. doi: 10.1016/j.ygyno.2010.07.026. Epub 2010 Aug 24. Gynecol Oncol. 2010. PMID: 20797776 Review.
Cited by
- Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity.
Wojnarowicz P, Gambaro K, de Ladurantaye M, Quinn MC, Provencher D, Mes-Masson AM, Tonin PN. Wojnarowicz P, et al. Oncogenesis. 2012 Sep 10;1(9):e27. doi: 10.1038/oncsis.2012.25. Oncogenesis. 2012. PMID: 23552840 Free PMC article. - DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines.
Houshdaran S, Hawley S, Palmer C, Campan M, Olsen MN, Ventura AP, Knudsen BS, Drescher CW, Urban ND, Brown PO, Laird PW. Houshdaran S, et al. PLoS One. 2010 Feb 22;5(2):e9359. doi: 10.1371/journal.pone.0009359. PLoS One. 2010. PMID: 20179752 Free PMC article. - Folate Transport and One-Carbon Metabolism in Targeted Therapies of Epithelial Ovarian Cancer.
Wallace-Povirk A, Hou Z, Nayeen MJ, Gangjee A, Matherly LH. Wallace-Povirk A, et al. Cancers (Basel). 2021 Dec 31;14(1):191. doi: 10.3390/cancers14010191. Cancers (Basel). 2021. PMID: 35008360 Free PMC article. Review. - Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review.
Smith HJ, Straughn JM, Buchsbaum DJ, Arend RC. Smith HJ, et al. Gynecol Oncol Rep. 2017 Mar 21;20:81-86. doi: 10.1016/j.gore.2017.03.007. eCollection 2017 May. Gynecol Oncol Rep. 2017. PMID: 28378010 Free PMC article. Review. - Histone Modifying Enzymes in Gynaecological Cancers.
Ramarao-Milne P, Kondrashova O, Barry S, Hooper JD, Lee JS, Waddell N. Ramarao-Milne P, et al. Cancers (Basel). 2021 Feb 16;13(4):816. doi: 10.3390/cancers13040816. Cancers (Basel). 2021. PMID: 33669182 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous